MyChoice CDx
Myriad Genetic Laboratories, Inc. · Decision date Mar 10, 2026
What did the FDA approve?
FDA records P190014/S011 as a supplement to PMA P190014, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Mar 10, 2026.
FDA approval order statement
Approval to update the MyChoice CDx assay labeling from a complementary diagnostic to a companion diagnostic to aid in identifying ovarian cancer patients with deleterious or suspected deleterious germline or somatic BRCA1 and BRCA2 mutations and/or a positive genomic instability score, who are eligible or may become eligible for treatment with Zejula (niraparib).
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Pathology
- Decision date
- Mar 10, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P190014/S011
- Regulatory pathway
- PMA supplement
- Applicant
- Myriad Genetic Laboratories, Inc.
- Product code
- PJG
- Decision code
- APPR
- Decision date
- Mar 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cancer-related germline gene mutation detection system.
- Applicant
- Myriad Genetic Laboratories, Inc.
- Product code
- PJG
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P190014/S011 received
Application receipt date recorded by FDA.
P190014/S011 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P190014. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Myriad Genetic Laboratories, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 320 Wankara Way, Salt Lake City, UT, 84108
Sources and methodology
- Original FDA record: P190014/S011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records